D-Rise® 40000 Capsule: Each capsule contains Cholecalciferol USP 40000 IU.
D-Rise® 20000 Capsule: Each capsule contains Cholecalciferol USP 20000 IU.
D-Rise® 2000 Tablet: Each tablet contains Cholecalciferol USP 2000 IU.
D-Rise® is a preparation of Cholecalciferol, a synthetic form of Vitamin D3. It is essential for normal bone growth and development and to maintain bone density. Cholecalciferol helps our body to utilize both Calcium and Phosphorus. It acts as a hormone and increases reabsorption of Calcium and Phosphorus by the kidneys.
Prevention and Treatment of Cholecalciferol deficiency states.
Studies have shown safe use of doses up to 4000 IU during pregnancy. The recommended daily intake for pregnant women is 400 IU, however, in women who are considered to be Cholecalciferol deficient a higher dose may be required. During pregnancy women should follow the advice of their medical practitioner as their requirements may vary depending on the severity of their disease and their response to treatment.
Cholecalciferol and its metabolites are excreted in breast milk. Overdose in infants induced by nursing mothers has not been observed; however, when prescribing additional Cholecalciferol to a breast-fed child the practitioner should consider the dose of any additional Cholecalciferol given to the mother.
### Adults:
Treatment of Cholecalciferol deficiency:
40,000 IU/week for 7 weeks, followed by maintenance therapy (1400-2000 IU/day).
Follow-up 25 (OH)D measurements should be made approximately 3 to 4 months after initiating maintenance therapy to confirm that the target level has been achieved.
Prevention of Vitamin D deficiency: 20,000 IU/Month.
### Children:
Treatment of Vitamin D deficiency, 12-18 years: 20,000 IU, once every 2 weeks for 6 weeks.
Prevention of Vitamin D deficiency, 12-18 years: 20,000 IU, once every 6 weeks.
Cholecalciferol is known to interact with Carbamazepine, Dactinomycin, Diuretics, Fosphenytoin, Miconazole, Phenobarbital, Phenytoin, Primidone
#NAME?
The frequency of the undesirable effects listed below;
Metabolism and nutrition disorders:
Uncommon (≥1/1000 to <1/100): Hypercalcaemia and hypercalciuria.
Gastrointestinal disorders: Rare (≥1/10,000 to <1/1000): Constipation, flatulence, bloating, abdominal distension, nausea, abdominal pain, diarrhoea.
Skin and subcutaneous tissue disorders: Rare (≥ 1/10,000 to < 1/1,000): Pruritus, rash and urticaria
Studies have shown safe use of doses up to 4000 IU during pregnancy. The recommended daily intake for pregnant women is 400 IU, however, in women who are considered to be Cholecalciferol deficient a higher dose may be required. During pregnancy women should follow the advice of their medical practitioner as their requirements may vary depending on the severity of their disease and their response to treatment.
Cholecalciferol and its metabolites are excreted in breast milk. Overdose in infants induced by nursing mothers has not been observed; however, when prescribing additional Cholecalciferol to a breast-fed child the practitioner should consider the dose of any additional Cholecalciferol given to the mother.
Cholecalciferol should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. Caution is required in patients receiving treatment for cardiovascular disease as the administration of Cholecalciferol may increase the risk of digitalis toxicity (arrhythmia). Cholecalciferol should also be prescribed with caution in patients with sarcoidosis.
There is no clear evidence for causation between Cholecalciferol supplementation and renal stones, but the risk is plausible, especially in the context of concomitant calcium supplementation.
Medical supervision is required whilst on treatment to prevent hypercalcaemia.
Keep out of the reach of children. Keep in a cool & dry place. Protect from light.
Keep out of the reach of children. Keep in a cool & dry place. Protect from light.